BiotechTube
CKP Therapeutics

CKP Therapeutics

Cambridge, United States· Est.
ckptherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

CKP Therapeutics is dedicated to lengthening life expectancy and improving quality of life for patients with refractory advanced cancers. The company employs a unique drug discovery platform to identify compounds that directly target cancer stem cells (CSCs), a key driver of recurrence and metastasis, by inhibiting the SERCA protein. Its strategy involves developing both combination therapies with standard treatments and stand-alone therapeutics, with an initial focus on solid tumors representing 90% of adult cancer cases. The team comprises experienced business, legal, and medical experts driving the translation of frontier cancer research into clinical solutions.

OncologySolid Tumors

Technology Platform

A proprietary drug discovery platform that directly targets Cancer Stem Cells (CSCs) by inhibiting the SERCA protein, integrated with PDC/PDX models to identify novel compounds for refractory cancers.

Opportunities

The significant unmet need in refractory advanced cancers presents a large market opportunity.
Successfully targeting cancer stem cells could lead to paradigm-shifting, durable treatments for recurrent and metastatic disease.
The platform's potential to generate multiple drug candidates for various solid tumors offers a pipeline expansion opportunity.

Risk Factors

High scientific risk associated with the novel SERCA inhibition mechanism.
As a private, preclinical company, securing sufficient funding to reach clinical trials is a major challenge.
Intense competition in oncology from larger, well-resourced companies.

Competitive Landscape

Competes with companies targeting cancer stem cells through indirect pathway inhibition (e.g., Notch, Hedgehog). Differentiation lies in the direct targeting of CSCs via SERCA inhibition. Faces competition from large pharma with broad oncology pipelines and significant R&D budgets.

More companies in Oncology (General) →More companies in United States →